Organization
National Cancer Institute, Vilnius, Lithuania
77 abstracts
Abstract
Single point of entry to the European precision cancer medicine trial network PRIME-ROSE.Org: Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital and University of Oslo, Oslo, Norway, National Cancer Institute, Vilnius, Lithuania, The Swedish Institute for Health Economics, Lund, Sweden, Oslo University Hospital, Division of Cancer Medicine, Oslo, Norway, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland,
Abstract
Soluble mesothelin neutralizes mesothelin antibody-based therapies.Org: Mayo Clinic, National Cancer Institute, Vilnius, Lithuania,
Abstract
A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors.Org: Ankyra Therapeutics, National Cancer Institute, Vilnius, Lithuania, UPMC Hillman Cancer Center,
Abstract
Assessing the missions and visions of NCI-designated cancer centers and their affiliated hospitals.Org: University of Oklahoma College of Medicine, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, University of Oklahoma Health Sciences Center, UT Southwestern Medical Center, National Cancer Institute, Vilnius, Lithuania,
Abstract
Chemotherapy-induced peripheral neuropathy research: A National Institute of Health (NIH) grant portfolio analysis.Org: National Cancer Institute, Vilnius, Lithuania, Division of Cancer Prevention, Georgetown University Lombardi Comprehensive Cancer Center,
Abstract
Association of a polygenic risk score with risk of abnormal ultrasound findings and ovarian cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.Org: National Cancer Institute, Vilnius, Lithuania, American Cancer Society, National Institutes of Health All of Us Research Program,
Abstract
Representation of Hispanics with liver cancer in oncology genotype databases.Org: Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program,
Abstract
Health insurance plans offered at NCI-designated cancer centers.Org: University of Oklahoma College of Medicine, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, University of Oklahoma Health Sciences Center, UT Southwestern Medical Center, The University of Oklahoma Stephenson Cancer Center,
Abstract
PRGN-2012, a novel gorilla adenovirus-based immunotherapy, provides the first treatment that leads to complete and durable responses in recurrent respiratory papillomatosis patients.Org: National Cancer Institute, Vilnius, Lithuania, Center for Immune-Oncology, Center for Cancer Research, National Cancer Institute, Precigen, Inc., National Institutes of Health All of Us Research Program,
Abstract
A phase Ib/II study of an anti-CD137 agonist antibody ADG106 in combination with weekly paclitaxel and dose-dense doxorubicin/cyclophosphamide.Org: National University Cancer Institute, National University Health Systems, National Cancer Institute, Vilnius, Lithuania,
Abstract
Symptom burden in adolescents and young adults with cancer: A subgroup analysis of the enhanced, EHR-facilitated cancer symptom control (E2C2) trial.Org: Mayo Clinic, Rochester, MN, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indianapolis, IN, Scottsdale, AZ,
Abstract
Identifying digital pathology imaging based biomarkers of checkpoint inhibitor response in non-small cell lung cancer.Org: National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Bethesda, VA, Bethesda, MD, SUNY Upstate Medical University,
Abstract
Randomized phase II/III study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701.Org: Massachusetts General Hospital, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, Mayo Clinic, National Cancer Institute, Vilnius, Lithuania,
Abstract
Tazemetostat in combination with topotecan and pembrolizumab in patients with recurrent small cell lung cancer.Org: Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA, Philadelphia, PA, National Cancer Center Hospital East, Kashiwa, Japan, Shinjuku-Ku, Japan,
Abstract
Altering the gut microbiome and TME in advanced liver cancers: A phase II study of nivolumab, tadalafil, and oral vancomycin in refractory HCC or liver-dominant metastatic CRC or PDAC.Org: Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program,
Abstract
Molecular profiling of ctDNA from NCI-MATCH patients enrolled for treatment with mTOR1/2 inhibitor sapanisertib (arm M) and the Hedgehog pathway inhibitor vismodegib (arm T).Org: Illumina, Inc., Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Vilnius, Lithuania, Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD,
Abstract
Phase 1B study of avelumab and whole brain radiotherapy (WBRT) in patients with leptomeningeal disease (LMD) from epithelial carcinomas: Final results and molecular analyses with single cell RNA sequencing.Org: Moffitt Cancer Center, H. Lee Moffitt Cancer Center and Research Institute, Moffitt Cancer Center and Research Institute, National Cancer Institute, Vilnius, Lithuania,
Abstract
Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.Org: Dana-Farber Cancer Institute, Mayo Clinic, Harvard Medical School, Brigham and Women's Hospital/Massachusetts General Hospital, National Cancer Institute, Vilnius, Lithuania,
Abstract
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers.Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, Il-Yang Pharmaceuticals, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Seattle Gummy Company,
Abstract
Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials.Org: Fred Hutchinson Cancer Research Center, Seattle, WA, American Society of Clinical Oncology, Alexandria, VA, Friends of Cancer Research, Washington, DC,
Abstract
A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.Org: National Cancer Institute, Vilnius, Lithuania, NYU Langone Laura and Isaac Perlmutter Cancer Center, Dana-Farber Cancer Institute, University of California Davis, Sacramento, CA, University of Colorado Cancer Center Anschutz Medical Campus,
Abstract
Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China, Guangzhou Institute of Respiratory Health, National Cancer Institute, Vilnius, Lithuania,
Abstract
Dissecting small cell lung cancer subtypes with cell-free DNA fragmentomes.Org: Delfi Diagnostics, Inc., National Cancer Center Hospital East, Kashiwa, Japan, National Cancer Institute, Vilnius, Lithuania, DELFI Diagnostics, The Johns Hopkins University School of Medicine,
Abstract
Gynecologic-cancer analysis of ARID1A alterations detected in tissue and liquid biopsies.Org: Foundation Medicine, Inc., Cambridge, MA, National Cancer Institute, Vilnius, Lithuania,
Abstract
Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.Org: Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, Princess Margaret Cancer Centre, University of Toronto,
Abstract
Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate, in patients (pts) with advanced prostate cancer.Org: Carolina Urologic Research Center, Oncology Hematology Consultants Ltd., First Urology, Urology Cancer Center, PC, National Cancer Institute, Vilnius, Lithuania,
Abstract
Sex differences in cancer incidence rates by race and ethnicity: Results from the Surveillance, Epidemiology, and End Results (SEER) Registry (2000-2019).Org: National Cancer Institute, Vilnius, Lithuania, DCGE National Cancer Inst,
Abstract
Prediction of cancer treatment response from histopathology images through imputed transcriptomics.Org: Pangea Biomed, University of Pittsburgh, Pittsburgh, PA, Sheba Medical Center at Tel-Hashomer, University of Colorado School of Medicine, Department of Oncology and Cancer Research UK Cambridge Institute,
Abstract
SEER analysis of 9-year breast cancer specific mortality (BCSM) in patients (pts) with invasive lobular breast cancer (ILC) assessed by the 21-gene Breast Recurrence Score assay.Org: UPMC Hillman Cancer Center, Genomic Health Inc, NSABP Foundation, University of Pittsburgh, Pittsburgh, PA, Exact Sciences Corporation,
Abstract
A phase 2 single-arm study of berzosertib in combination with irinotecan in patients with progressive TP53 mutant gastric and gastro-esophageal junction cancer.Org: Vanderbilt University Medical Center, Hunstman Cancer Hospital, University of Utah Health, University of Utah, University of California Irvine, University of Pittsburgh Medical Center (UPMC),
Abstract
Genomic characterization of somatic mutations by race and ethnicity in pancreatic cancer defined through AACR project GENIE.Org: Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program,
Abstract
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.Org: City of Hope National Medical Center, Fred Hutchiinson Cancer Research Center, SWOG Statistics and Data Management Center, Seattle, WA, Johns Hopkins University School of Medicine, University of Pennsylvania,
Abstract
Molecular classification of cancer site of origin and lineage.Org: National Institutes of Health All of Us Research Program, National Cancer Institute, Vilnius, Lithuania, Bethesda, MD, Department of Human Oncology, University of Wisconsin, Madison, WI,
Abstract
Discovery of gene fusions in driver-negative NCI-MATCH screening samples.Org: Massachusetts General Hospital/Harvard Medical School, Frederick National Laboratory for Cancer Research, Yale University, Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, National Cancer Institute, Vilnius, Lithuania,
Abstract
RANO 2.0: Proposal for an update to the Response Assessment in Neuro-Oncology (RANO) Criteria for high- and low-grade gliomas in adults.Org: Dana-Farber Cancer Institute, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Ronald Reagan UCLA Medical Center, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, Stanford University, Stanford, CA, California Pacific Medical Center Research Institute, San Francisco, CA, Women's Health Integrated Research Center at Inova Health System, Annandale, VA, Women’s Health Integrated Research Center at Inova Health System, Department of Defense Gynecologic Cancer Center of Excellence, Annandale, VA, Stanford University Medical Center, Palo Alto, CA, Pingtung Veterans General Hospital, Pingtung, South Korea, University Hospital and University of Zurich,
Abstract
Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome.Org: Pangea Biomed, National Cancer Institute, Vilnius, Lithuania, Cancer Data Science Laboratory (CDSL), National Institutes of Health All of Us Research Program, Women’s Malignancies Branch,
Abstract
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, UC San Diego Moores Cancer Center, University of Kansas Medical Center, Department of Biostatistics & Data Science, Loma Linda University Department of Radiation Technology,
Abstract
SARC037: Results of phase I study of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in relapsed/refractory Ewing sarcoma (ES).Org: Children's Hospital of Philadelphia, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Pediatric Oncology Branch, Clinical Center National Institutes of Health, Clinical Center National Institutes of Health, NIH / NCI,
Abstract
The role of innate immune system in modulating CHK1 inhibitor (CHK1i) response in BRCA wild-type (BRCAwt), platinum-resistant high-grade serous ovarian cancer (PR-HGSOC): Exploratory analysis from a phase II study of CHK1i prexasertib.Org: Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Bethesda, MD,
Abstract
Association of 18F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies.Org: National Cancer Institute, Vilnius, Lithuania, National Institutes of Health Division of Occupational Health and Safety, Genitourinary Malignancies Branch, CCRT/The Caroline Foundation, NCI,
Abstract
A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL).Org: Genitourinary Malignancies Branch, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute,
Abstract
Use of real-world evidence to benchmark clinical trial results: A case study in von Hippel-Lindau (VHL) disease.Org: National Cancer Institute, Vilnius, Lithuania, Merck & Co., Inc., IQVIA, Amsterdam, Netherlands, National Cancer Institute/National Institutes of Health,
Abstract
Mismatch repair deficiency and microsatellite instability-high in urothelial carcinoma: A systematic review and meta-analysis.Org: National Cancer Institute, Vilnius, Lithuania, Memorial Sloan Kettering Cancer Center, National Institutes of Health All of Us Research Program,
Abstract
A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies.Org: Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, NYU Langone Laura and Isaac Perlmutter Cancer Center, Genitourinary Malignancies Branch,
Abstract
Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.Org: St. James’s Hospital, Dana-Farber Cancer Institute, University of Texas MD Anderson Cancer Center, Jefferson Kimmel Cancer Center at Jefferson Health, NCI,
Abstract
Investigation of cancer predisposition in Fanconi anemia heterozygotes: A DiscovEHR cohort population study.Org: National Cancer Institute, Vilnius, Lithuania, Geisinger Medical Center,
Abstract
Safety, efficacy and biomarker data in non-small cell lung cancer patients treated with the anti-IL1RAP antibody nadunolimab in combination with platinum doublet.Org: Hospital Universitario 12 de Octubre, Madrid, Spain, Centre Hospitalier Universitaire de Liège, Liège, Belgium, Department of Pulmonology Medical Academy Lithuania University of Health Sciences, Kaunas, Lithuania, National Cancer Institute, Vilnius, Lithuania, Riga East Clinical University Hospital, Riga, Latvia,
Abstract
Longitudinal follow-up and outcomes of pediatric and adult patients with SDH-deficient GIST.Org: Pediatric Oncology Branch, Clinical Center National Institutes of Health, Center for Cancer Research, National Cancer Institute, Surgical Oncology Program, Developmental Therapeutics Branch, National Cancer Institute, Vilnius, Lithuania,
Abstract
Epidemiologic effectors on the breast tumor microenvironment: Results from the Cancer Prevention Study-II and -3 cohorts.Org: John H. Stroger, Jr. Hospital of Cook County, Northwestern University Feinberg School of Medicine, American Cancer Society, National Cancer Institute, Vilnius, Lithuania, Robert H. Lurie Comprehensive Cancer Center, Northwestern University,
Abstract
Congenital anomalies and health outcomes among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.Org: Baylor College of Medicine, Children's Hospital of Philadelphia, National Cancer Institute, Vilnius, Lithuania, Duke University Trent Center for Bioethics Humanities and History of Medicine, Durham, NC, University of Alabama at Birmingham School of Medicine,
Abstract
Associations of employment disruptions and financial hardship among individuals diagnosed with cancer in the US.Org: National Cancer Institute, Vilnius, Lithuania, American Cancer Society,
Abstract
Intraarterial chemotherapy of liver metastases of colorectal cancer. Experience of National Cancer Institute of Ukraine.Org: National Cancer Institute of Ukraine, Kyiv Regional Oncology Center, Ukraine, National Cancer Institute, Vilnius, Lithuania,
Abstract
Impact of fludarabine exposure on the depth and duration of lymphopenia and CAR T-cell outcomes.Org: Pediatric Oncology Branch, Clinical Center National Institutes of Health, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, Nihon Medi-Physics, Pharmacy Department,
Abstract
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.Org: Moffitt Cancer Center and Research Institute, Southwest Oncology Group Statistical Center, UPMC Hillman Cancer Center, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, Columbia University Irving Medical Center, New York, NY, USA,
Abstract
Associations between psychosocial and lifestyle factors and biological age acceleration among long-term survivors of childhood cancer: A prospective study from the St. Jude Lifetime Cohort.Org: National Cancer Institute, Vilnius, Lithuania, Rockville, MD, St. Jude Children's Research Hospital, Memphis, TN, Columbia University - Mailman School of Public Health,
Abstract
Xenonucleic acid technology in high-sensitivity IDH1/2 mutation detection for glioma molecular profiling.Org: DiaCarta, Inc., National Cancer Institute, Vilnius, Lithuania,
Abstract
Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1 or SMARCA4 deficient tumors.Org: Pediatric Oncology Branch, Clinical Center National Institutes of Health, NCI, Nihon Medi-Physics, National Cancer Institute, Vilnius, Lithuania, Institute for Clinical and Translational Research, Baylor College of Medicine,
Abstract
Association of major adverse financial events and later stage cancer diagnosis in the US.Org: American Cancer Society, National Cancer Institute, Vilnius, Lithuania, Information Management Services, Inc., University Washington, Emory University, Atlanta, GA, USA,
Abstract
Long-term outcomes in a population-based cohort of 2,967 uveal melanoma patients clinically tested with the 15-gene expression profile: A collaborative study with the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program Registries.Org: Castle Biosciences, Inc., Friendswood, TX, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Rockville, MD,
Abstract
Integrating the 31-gene expression profile test into clinical decision-making to guide risk-aligned care decisions for patients with stage I-III cutaneous melanoma: NCI-SEER Analysis.Org: Desert Surgical Oncology, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Castle Biosciences, Castle Biosciences, Inc.,
Abstract
Association of HRD ovarian cancer by RAD51 with hot immune microenvironment: Translational analyses of MITO 16A/MaNGO-OV2 trial.Org: University of Parma, Department of Molecular Medicine and Surgery, Federico II University of Naples, Cannizzaro Hospital of Catania, University Hospital of Parma,
Abstract
Phase II trial evaluating nivolumab in patients with recurrent IDH-mutant gliomas with and without hypermutation phenotype.Org: Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Bethesda, MD,
Abstract
Survival outcomes of BRCA1/BRCA2 mutated breast cancers: Study from a tertiary care cancer centre in India.Org: All India Institute of Medical Sciences (AIIMS), Rishikesh, India, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, BRA-IRCH, National Cancer Institute, Vilnius, Lithuania, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan,
Abstract
Older adults (OA) in clinical trials: Where are they? Representation of OA in clinical trials conducted at the National Cancer Institute (NCI) Clinical Center.Org: Genitourinary Malignancies Branch, CCRT/The Caroline Foundation, NCI, Nihon Medi-Physics, Medical Oncology Service,
Abstract
Chemotherapy induced peripheral neuropathy (CIPN) and biomarkers of gut microbial translocation in long-term survivors of testicular germ cell tumors.Org: National Cancer Institute, Vilnius, Lithuania, Comenius University, Bratislava, Slovakia, Institute of Molecular Biomedicine,
Abstract
FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes.Org: National Cancer Institute, Vilnius, Lithuania, Nihon Medi-Physics, Cleveland Clinic Taussig Cancer Instititute, Medical College of Wisconsin, NYU Langone Laura and Isaac Perlmutter Cancer Center,
Abstract
Preclinical efficacy of NXP900, a YES1/SRC kinase inhibitor in esophageal squamous cancer models.Org: National Cancer Institute, Vilnius, Lithuania, University of Edinburgh Cancer Research UK Centre, Nuvectis Pharma,
Abstract
A phase II study of tremelimumab, durvalumab, and bevacizumab in advanced biliary tract cancers.Org: Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Laboratory of Pathology, NCI, NIH, Bethesda, MD,
Abstract
Barriers, facilitators, and strategies for improving breast cancer screening in Ukraine.Org: Brigham and Women’s Hospital, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Swiss Agency For Development And Cooperation - project Medical Education Development in Ukraine, National Cancer Institute, Vilnius, Lithuania, The University Hospital in Krakow,
Abstract
Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.Org: Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, TX, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for human uterine sarcoma cells.Org: Cancer Biology Department, National Cancer Institute, Vilnius, Lithuania, Cairo University, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, University of Chicago,
Abstract
Understanding cancer treatment decision making among cancer survivors.Org: National Cancer Institute, Vilnius, Lithuania, Rockville, MD, Bethesda, MD, National Cancer Institute (Bethesda, MD),
Abstract
Association of surgery and radiotherapy with risk of thoracic soft tissue sarcoma among older survivors of breast cancer.Org: National Institutes of Health All of Us Research Program, Bethesda, VA, MD Anderson Cancer Center, National Cancer Institute, Vilnius, Lithuania, NCI/NIH,
Abstract
Mass cytometry immune profiling to detect signatures of clinical activity of bintrafusp alfa (BA) in patients with advanced non-small cell lung cancer (NSCLC).Org: Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Teiko Bio,
Abstract
Primary care utilization and cardiovascular screening in adult-aged survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).Org: Cancer and Blood Disorders Center, Seattle Children's Hospital, University of Alberta, University of Washington and Fred Hutchinson Cancer Research Centre, St. Jude Children's Research Hospital,
Abstract
Outcome differences by sex in oncology clinical trials.Org: Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, Medical College of Wisconsin, WIN Consortium,
Abstract
A funder-based comparison of global oncology research led by NCI-designated cancer centers: Results from the 2021 Global Oncology Survey.Org: Center for Global Health, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Rockville, MD, Indiana University Melvin and Bren Simon Comprehensive Cancer Center,